Immune responses to Epstein-Barr virus lytic proteins in patients with nasopharyngeal carcinoma

Journal of Medical Virology

Volumn 73, Issue 4, 2004, Pages 574-582

  Liu, Mei Ying ^a,b   Huang, Yu Tzu ^a   Sheen, Tzung Shiahn ^a   Chen, Jen Yang ^a,c   Tsai, Ching Hwa ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIPEI UNIVERSITY OF NURSING AND HEALTH SCIENCES   (Taiwan)

^c NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

EBV lytic proteins; Immunity; NPC

Indexed keywords

DEOXYRIBONUCLEASE; DIFFUSED EARLY ANTIGEN; EARLY ANTIGEN; GENE PRODUCT; IMMUNOGLOBULIN A ANTIBODY; LYTIC PROTEIN; PROTEIN BMRF1; THYMIDINE KINASE; UNCLASSIFIED DRUG; VIRUS CAPSID ANTIGEN; VIRUS PROTEIN;

ANTIBODY TITER; ANTIGEN EXPRESSION; ARTICLE; BACULOVIRUS EXPRESSION SYSTEM; BLOOD CELL; CELL PROLIFERATION; CELLULAR IMMUNITY; CERVICAL LYMPH NODE; CONTROLLED STUDY; DNA SYNTHESIS; EPSTEIN BARR VIRUS; HUMAN; HUMAN TISSUE; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOFLUORESCENCE TEST; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; NASOPHARYNX CARCINOMA; TAIWAN; VIRUS REPLICATION;

ANIMALS; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; BACULOVIRIDAE; CELLS, CULTURED; DEOXYRIBONUCLEASES; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNITY; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; NASOPHARYNGEAL NEOPLASMS; RECOMBINANT PROTEINS; SPODOPTERA; THYMIDINE KINASE;

HUMAN HERPESVIRUS 4; UNIDENTIFIED BACULOVIRUS;

EID: 3042821644     PISSN: 01466615     EISSN: None     Source Type: Journal    
DOI: 10.1002/jmv.20128     Document Type: Article

References (46)

1. Andersson A, Vetter V, Kreutzer L, Bauer G. 1994. Avidities of IgG directed against viral capsid antigen or early antigen: Useful markers for significant Epstein-Barr virus serology. J Med Virol 43:238-244.
2. Brooks L, Yao QY, Rickinson AB, Young LS. 1992. Epstein-Barr virus latent gene transcription in nasopharygeal carcinoma cells: Coexpression of EBNA1, LMP1, and LMP2 transcripts. J Virol 66:2689-2697.
3. Cayrol C, Flemington EK. 1995. Identification of cellular target genes of the Epstein-Barr virus transactivator Zta: Activation of transforming growth factor βigh3 (TGF-βigh3) and TGF-β1. J Virol 69:4206-4212.
4. Chan SH, Chew TS, Goh EH, Simons MJ, Shanmugaratnam K. 1976. Impaired general cell-mediated immune functions in vivo and in vitro in patients with nasopharyngeal carcinoma. Int J Cancer 18:139-144.
5. Chen JY, Hwang LY, Beasley RP, Chien CS, Yang CS. 1985a. Antibody response to Epstein-Barr virus-specific DNase in 13 patients with nasopharyngeal carcinoma in Taiwan: A retrospective study. J Med Virol 16:99-105.
6. Chen JY, Liu MY, Chen CJ, Hsu MM, Tu SM, Lee HH, Kuo SL, Yang CS. 1985b. Antibody to Epstein-Barr virus-specific DNase as a marker for the early detection of nasopharyngeal carcinoma. J Med Virol 17:47-49.
7. Cheng YC, Chen JY, Glaser R, Henle W. 1980. Frequency and levels of antibodies to Epstein-Barr virus-specific DNase are elevated in patients with nasopharyngeal carcinoma. Proc Nat Acad Sci USA 77:6162-6165.
8. Cheng HM, Foong YT, Sam CK, Prasad U, Dillner J. 1991. Epstein-Barr virus nuclear antigen 1 linear epitopes that are reactive with immunoglobulin A (IgA) or IgG in sera from nasopharyngeal carcinoma patients or from healthy donors. J Clin Microl 29:2180-2186.
9. Cochet C, Martel-Renoir D, Grunewald V, Bosq J, Cochet G, Schwaab G, Bernaudin JF, Joab I. 1993. Expression of the Epstein-Barr virus immediate early gene, BZLF1, in nasopharyngeal carcinoma tumour cells. Virology 197:358-365.
10. de-Vathaire F, Sancho H, de-The H, Schwaab G, Ho JHC, Ellouz R, Micheau C, Cammoun M, Cachin Y, de-The G. 1988. Prognostic value of EBV markers in the clinical management of nasopharyngeal carcinoma (NPC): A multicenter follow-up study. Int J Cancer 42:176-181.
11. Elioponlos AG, Stack M, Dawson CW, Kaye KM, Hodgkin L, Sihota S, Rowe M, Young LS. 1997. Epstein-Barr virus-encoded LMP-1 and CD40 mediate IL-6 production in epithelial cell via an NF-kB pathway involving TNF receptor-associated factors. Oncogene 14:2899-2916.
12. Frsch B, Zimber-Strobl U, Yip TTC, Lau WH, Mueller-Lantzsch N. 1993. Characterization of the antibodies response to the latent infection terminal proteins of Epstein-Barr virus in patients with nasopharyngeal carcinoma. J Gen Virol 74:811-818.
13. Hadar T, Rhahima M, Kahan E, Sidi J, Rakowsky E, Sarov B, Sarov I. 1986. Siginficance of specific Epstein-Barr virus IgA and elevated IgG antibodies in nasopharynageal carcinoma patients. J Med Virol 20:329-339.
14. Henle W, Henle G. 1979. Seroepidemiology of the virus. In: Epstein MA, Achong BG, editors. The Epstein-Barr virus. New York: Springer Verlag. pp 61-78.
15. Henle W, Ho JHC, Henle G, Chau JCW, Kwan HC. 1977. Nasopharyngeal carcinoma: Significance of changes in Epstein-Barr virus-related antibody patterns following therapy. Int J Cancer 20:663-672.
16. Hsu MM, Lin BL. 1986. Characterization of T cell subsets using monoclonal antibodies in nasopharyngeal carcinoma patients. Ann Otol Rhinol Laryngol 95:298-301.
17. Hsu MM, Ko JY, Chang YL. 1991. Elevated levels of soluble interleukin 2 receptor and tumour necrosis factor in nasopharyngeal carcinoma. Arch Otolaryngol Head Neck Surg 117:1257-1259.
18. + T cells. Cancer Res 59:1599-1605.
19. Joab I, Nicolas JC, Schwaab G, de-The G, Clausse B, Perricaudet M, Zeng Y. 1991. Detection of anti-Epstein-Barr virus transactivator (ZEBRA) antibodies in sera from patients with nasopharyngeal carcinoma. Int J Cancer 48:647-649.
20. Lin SF, Hsu TY, Liu MY, Lin LS, Yang HL, Chen JY, Yang CS. 1995. Characterization of Epstein-Barr virus DNase and its interaction with the major DNA binding protein. Virology 208:712-722.
21. Littler E, Newman W, Arrand JR. 1990. Immunological response of nasopharyngeal carcinoma patients to the Epstein-Barr-virus-coded thymidine kinase expressed in Escherichia coli. Int J Cancer 45:1028-1032.
22. Littler E, Baylis SA, Zeng Y, Conway MJ, Mackett M, Arrand JR. 1991. Diagnosis of nasopharyngeal carcinoma by means of recombinant Epstein-Barr virus proteins. Lancet 337:685-689.
23. Liu MY, Cho WH, Nutter L, Hsu MM, Chen JY, Yang CS. 1989. Antibody against Epstein-Barr virus DNA polymerase activity in sera of patients with nasopharyngeal carcinoma. J Med Virol 28:101-105.
24. Liu MY, Pai CY, Shieh SM, Hsu TY, Chen JY, Yang CS. 1992. Cloning and expression of a cDNA encoding the Epstein-Barr virus thymidine kinase gene. J Virol Methods 40:107-118.
25. Lo YM, Chan YS, Lo KW, Leung SF, Zhang J, Chan TC, Lee CK, Hjelm NM, Johnson PJ, Huang DP. 1999. Quantitative analysis of cell free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Res 59:1188-1191.
26. Luka J, Kallin B, Klein G. 1979. Induction of the Epstein-Barr virus (EBV) cycle in the latently infected cells by N-butyrate. Virology 94:228-231.
27. Moss DJ, Chan SH, Burrows SR, Chew TS, Kane RG, Staples JA, Kunaratnam N. 1983. Epstein-Barr virus specific T-cell response in nasopharygeal carcinoma patients. Int J Cancer 32:301-305.
28. Peng JC, Sheen TS, Hsu MM. 1995. Nasopharyngeal carcinoma with dermatomyositis. Arch Otolaryngol Head Neck Surg 121:1298-1301.
29. Picchio GR, Kobayashi R, Kirven M, Baird SM, Kipps TJ, Mosier D. 1992. Heterogeneity among Epstein-Barr virus-seropositive donors in the generation of immunoblastic B-cell lymphomas in SCID mice receiving human peripheral blood leukocyte graft. Cancer Res 52:2468-2477.
30. Pulvertaft RJV. 1965. A study of malignant tumours in Nigeria by short-term tissue culture. J Clin Pathol 18:261-273.
31. Ragona G, Ernberg I, Klein G. 1980. Induction and biological characterization of the Epstein-Barr virus (EBV) carried by the Jijoye lymphoma line. Virology 101:553-557.
32. Rickinson AB, Kieff E. 1996. Epstein-Barr virus. In: Fields BN, Knipes DM, Howley PM, editors. Virology. Philadelphia: Lippincott-Raven Publishers. pp 2397-2446.
33. Rochford R, Mosier DE. 1994. Immunobiology of Epstein-Barr virus-associated lymphomas. Clin Immunol Immuopathol 71:256-259.
34. Rowe M, Finke J, Szigeti R, Klein G. 1988. Characterization of the serological response in man to the latent membrane protein and the six nuclear antigens encoded by Epstein-Barr virus. J Gen Virol 69:1217-1228.
35. Sbih-Lammali F, Berger F, Busson P, Ooka T. 1996. Expression of the DNase encoded by the BGLF5 gene of Epstein-Barr virus in nasopharyngeal carcinoma epithelial cells. Virology 222:64-74.
36. Seigneurin JM, Lavoue MF, Genoulaz O, Bornkamm GW, Lenoir GM. 1987. Antibody response against the Epstein-Barr virus-coded nuclear antigen 2 (EBNA2) in different groups of individuals. Int J Cancer 40:349-353.
37. Starlz TE, Nalesnik MA, Porter KA, Ho M, Iwatsuki S, Griffith BP, Rosenthal JT, Hakala TR, Shaw BW, Hardesty RL, Atchinson RW, Jaff R, Bahnson HT. 1984. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-A-steroid therapy. Lancet 1:583-587.
38. Tsai CHA, Glaser R. 1991. A comparison of Epstein-Barr virus specific proteins expressed by three Epstein-Barr virus isolates using specific monoclonal antibodies. Intervirology 32:376-382.
39. Tsai CHA, Williams MV, Glaser R. 1991. Characterization of two monoclonal antibodies to Epstein-Barr virus diffuse early antigen wich react to two different epitopes and have different biological function. J Virol Methods 33:47-52.
40. Tsai CH, Liu MT, Chen MR, Lu J, Yang HL, Chen JY, Yang CS. 1997. Characterization of monoclonal antibodies to the zita and DNase proteins of Epstein-Darr virus. J Biomed Sci 4:69-77.
41. Tsurumi T, Daikoku T, Kurachi R, Nishiyama Y. 1993. Functional interaction between Epstein-Barr virus DNA polymerase catalytic subunit and its accessory subunit in vitro. J Virol 67:7648-7653.
42. Veronese ML, Veronesi A, D'Andera E, Mistro AD, Indraccolo S, Mazza MR, Mion M, Zamarchi R, Menin C, Panozzo M, Amadori A, Chieco-Bianchi L. 1992. Lymphoproliferative disease in human peripheral blood mononuclear cell-injected SCID mice. I. T lymphocyte requirement for B cell tumour generation. J Exp Med 176:1763-1767.
43. Wolf H, zur Hausen H, Becker V. 1973. Epstein-Barr viral genomes in epithelial nasopharyngeal carcinoma cells. Nature 244:245-247.
44. Xu J, Ahmad A, D'Addario M, Knafo L, Jones JF, Prasad U, Dolcetti R, Vaccher E, Menezes J. 2000. Analysis and significance of anti-latent membrane protein-1 antibodies in the sera of patients with EBV-associated diseases. J Immunol 164:2815-2822.
45. Yao M, Ohshima K, Suzumiya J, Kume T, Shiroshita T, Kikuchi M. 1997. Interleukin-10 expression and cytotoxic-T-cell response in Epstein-Barr-virus- associated nasopharyngeal carcinoma. Int J Cancer 72:398-402.
46. zur Hausen H, O'Neill FJ, Freese UK. 1978. Persisting oncogenic herpesvirus induced by the tumour promoter TPA. Nature 272:373-375.